公开(公告)号：US10899752B2

公开(公告)日：2021-01-26

申请号：US16394762

申请日：2019-04-25

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro Sugimoto ,  Shinkichi Suzuki ,  Hiroki Sakamoto ,  Masami Yamada ,  Minoru Nakamura ,  Makoto Kamata ,  Kenichiro Shimokawa ,  Masataka Murakami ,  Jinichi Yonemori ,  Takuto Kojima

IPC: C07D413/14 ,  C07D413/04 ,  C07D413/06 ,  C07D413/10 ,  C07D417/06 ,  C07D471/04 ,  C07D491/107 ,  C07D265/22 ,  C07F7/02 ,  A61P25/28 ,  C07D417/10 ,  C07F7/08

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

公开(公告)号：US10323027B2

公开(公告)日：2019-06-18

申请号：US15735418

申请日：2016-06-23

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro Sugimoto ,  Shinkichi Suzuki ,  Hiroki Sakamoto ,  Masami Yamada ,  Minoru Nakamura ,  Makoto Kamata ,  Kenichiro Shimokawa ,  Masataka Murakami ,  Jinichi Yonemori ,  Takuto Kojima

IPC: C07D413/14 ,  C07D413/04 ,  C07D413/06 ,  C07D413/10 ,  C07D417/06 ,  C07D471/04 ,  C07D265/22 ,  C07D491/107 ,  C07F7/02 ,  A61P25/28 ,  C07D417/10 ,  C07F7/08

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

公开(公告)号：US09789084B2

公开(公告)日：2017-10-17

申请号：US15608565

申请日：2017-05-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masami Yamada ,  Shinkichi Suzuki ,  Takahiro Sugimoto ,  Minoru Nakamura ,  Hiroki Sakamoto ,  Makoto Kamata

IPC: C07D209/46 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D405/14 ,  A61K31/4035 ,  A61K31/4406 ,  A61K31/045 ,  C07D471/04

CPC classification number: C07D405/14 ,  A61K31/045 ,  A61K31/13 ,  A61K31/325 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/55 ,  C07D209/46 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US09403802B2

公开(公告)日：2016-08-02

申请号：US14382390

申请日：2013-02-28

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Hiroki Sakamoto ,  Takahiro Sugimoto

IPC: C07D401/14 ,  C07D209/12 ,  C07D401/04 ,  C07D405/12 ,  C07D215/56 ,  C07D401/10 ,  C07D401/12 ,  C07D237/28 ,  C07D401/06 ,  C07D403/10

CPC classification number: C07D405/12 ,  C07D215/56 ,  C07D237/28 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D403/10

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, and useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, a sleep disorder and the like. The present invention relates to a compound represented by the formula (I): wherein R1 is an optionally substituted amino group or an optionally substituted cyclic amino group, R2 and R3 are each independently a hydrogen atom or a substituent, X is —CH═ or —N═, and ring A is an optionally substituted 5- to 10-membered ring, or a salt thereof.

Abstract translation: 本发明提供具有胆碱能毒蕈碱M1受体阳性变构调节剂活性的化合物，可用作阿尔茨海默病，精神分裂症，疼痛，睡眠障碍等的预防或治疗药物。 本发明涉及由式（I）表示的化合物：其中R 1为任选取代的氨基或任选取代的环状氨基，R 2和R 3各自独立地为氢原子或取代基，X为-CH =或 -N =，环A为任选取代的5至10元环或其盐。